Amended Quarterly Report (10-q/a)
March 29 2019 - 1:22PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON D.C. 20549
FORM 10-Q/A
Amendment No. 1
☒
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2018
OR
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
FOR THE TRANSITION PERIOD FROM
____
TO
____
.
COMMISSION FILE NUMBER: 001-37861
MABVAX THERAPEUTICS HOLDINGS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE
|
|
93-0987903
|
(STATE OR OTHER JURISDICTION OF
INCORPORATION OR ORGANIZATION)
|
|
(I.R.S. EMPLOYER
IDENTIFICATION NO.)
|
11535 Sorrento Valley Road, Suite 400, San Diego, CA
92121
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES INCLUDING ZIP
CODE)
(858) 259-9405
(REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA
CODE)
Indicate
by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for
the past 90
days. Yes
☒
No
☐
Indicate
by check mark whether the registrant has submitted electronically
every Interactive Data File required to be submitted pursuant to
Rule 405 of Regulation S-T (§232.405 of this chapter) during
the preceding 12 months (or for such shorter period that the
registrant was required to submit such
files). Yes
☒
No
☐
Indicate
by check mark whether the registrant is a large accelerated filer,
an accelerated filer, a non-accelerated filer, a smaller
reporting company or an emerging growth company. See the
definitions of “large accelerated filer,”
“accelerated filer,” “smaller reporting
company” and “emerging growth company” in
Rule 12b-2 of the Exchange Act.
Large
accelerated filer
|
☐
|
Accelerated
filer
|
☐
|
Non-accelerated
filer
|
☐
|
Smaller
reporting company
|
☒
|
Emerging
growth company
|
☐
|
|
|
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
☐
Indicate
by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Exchange
Act). Yes
☐
No
☒
The
number of shares of registrant’s common stock outstanding as
of March 29, 2019 was 9,429,582.
EXPLANATORY NOTE
We are
filing Amendment No. 1 to t
his
quarterly report on Form 10-Q
for the sole purpose of
including a revised Exhibit 10.1 that incorporates revisions to the
amount of text for which confidential treatment has been requested.
Exhibit 10.1 represents the Asset Purchase and License Agreement by
and between Boehringer Ingelheim International GMBH and MabVax
Therapeutics Holdings, Inc. and MabVax Therapeutics,
Inc.
Item
6.
Exhibits.
The
following is a list of exhibits filed as part of this Quarterly
Report on Form 10-Q.
|
|
|
Exhibit
No.
|
Exhibit Name
|
Filed
with this Form 10-Q
|
|
Asset Purchase and License Agreement with Boehringer Ingelheim
International GmbH
|
X
|
|
Certification
of Chief Executive Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
|
X
|
|
Certification
of Chief Financial Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
|
X
|
|
Certification
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
|
X
|
101*
|
Interactive
data file
|
|
*
Furnished herewith
†
Confidential treatment requested for portions of this exhibit.
Confidential materials omitted and filed separately with the
SEC.
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
|
|
Date:
March 29, 2019
|
MABVAX
THERAPEUTICS HOLDINGS, INC.
|
|
|
|
|
By:
|
/s/ J. David
Hansen
|
|
|
J.
David Hansen
|
|
|
President
and Chief Executive Officer
(Principal
Executive Officer authorized
to sign
on behalf of the registrant)
|
|
|
|
|
|
|
|
By:
|
/s/ Gregory P.
Hanson
|
|
|
Gregory
P. Hanson
|
|
|
Chief
Financial Officer
(Principal
Financial and Accounting Officer
authorized
to sign on behalf of the registrant)
|